Nuwellis, Inc. (NUWE)
| Market Cap | 392.76K -88.3% |
| Revenue (ttm) | 8.77M -0.2% |
| Net Income | -19.04M |
| EPS | -16.10 |
| Shares Out | 2.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,891,953 |
| Open | 0.1360 |
| Previous Close | 0.1335 |
| Day's Range | 0.1335 - 0.1430 |
| 52-Week Range | 0.1246 - 25.9500 |
| Beta | 0.17 |
| Analysts | Hold |
| Price Target | 462.00 (+345,967.42%) |
| Earnings Date | May 12, 2026 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Au... [Read more]
Financial Performance
In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NUWE stock is "Hold" and the 12-month stock price target is $462.0.
News
Nuwellis highlights clinical utility of its Aquadex SmartFlow system
Nuwellis (NUWE) highlighted the clinical utility of its Aquadex SmartFlow system at the 4th annual Critical Care Cardiology Education Summit, hosted by the University of Minnesota. As part of the…
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit
MINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the c...
Nuwellis CEO transition to transition out of role, Mike McCormick to succeed
Nuwellis (NUWE) announced the appointment of Mike McCormick as CEO, effective June 30. John Erb, who currently serves as president, CEO, and chairman of the board, will transition from his…
Nuwellis Appoints Mike McCormick as Chief Executive Officer
Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of th...
Nuwellis expands collaboration with South Carolina healthcare system
Nuwellis (NUWE) announced an expanded collaboration with a major South Carolina healthcare system to integrate Aquadex SmartFlow devices into the clinical care programs at one of its children’s hospit...
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's Hospitals
South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that already use the technology South Carolina healthcare provider also upgrades to latest Aquadex devic...
Nuwellis Announces Closing of $6.0 Million Registered Public Offering
MINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces ...
Nuwellis 20M share secondary priced at 30c
Nuwellis (NUWE) announces the pricing of a public offering of 20M shares of its common stock with accompanying warrants to purchase common stock for gross proceeds of approximately $6M. The…
Nuwellis Announces Pricing of $6 Million Public Offering
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces t...
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Nuwellis Slides: Investor presentation
Nuwellis has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Nuwellis files to sell 4.85M shares of common stock, warrants
Ladenburg Thalmann is acting as exclusive placement agent.
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Nuwellis completes Aquadex SmartFlow System pre-submission meeting with the FDA
Nuwellis (NUWE) announced the completion of a recent pre-submission meeting with the FDA regarding the proposed label expansion of the Aquadex SmartFlow System to support pediatric patients weighing 5...
Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label
Proposal would extend treatment access to pediatric patients weighing 5 kg and above Proposal would extend treatment access to pediatric patients weighing 5 kg and above
Nuwellis Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% revenue growth, improved gross margin, and a strengthened leadership team. Pediatrics now accounts for half of U.S. revenue, and a strategic acquisition expands the product portfolio. Cash burn reduction and disciplined capital allocation remain priorities.
Nuwellis Earnings release: Q1 2026
Nuwellis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Nuwellis Quarterly report: Q1 2026
Nuwellis has published its Q1 2026 quarterly earnings report on May 12, 2026.
Nuwellis, Inc. Announces First Quarter 2026 Financial Results
MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported fin...
Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026
MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will ...
Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting
Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure Poster present...
Nuwellis gets notice of allowance from USPTO for lumen midline catheter
Nuwellis (NUWE) announced that the U.S. Patent and Trademark Office, or USPTO, has issued a notice of allowance for a new patent covering its novel dual lumen midline catheter technology…
Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology
MINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that t...
Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530 Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth ...